ATAC - Arimidex, Tamoxifen Alone or in Combination

Sponsor
AstraZeneca
Study ID
NCT00849030
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
45 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Anastozole (Arimidex) — DRUG
    1mg, orally, once daily
  • Tamoxifen (Nolvadex) — DRUG
    20mg, orally, once daily
  • Anastozole (Arimidex) placebo — DRUG
    1mg, orally, once daily
  • Tamoxifen (Nolvadex) placebo — DRUG
    20mg, orally, once daily

Study Details

The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.

Key Dates

Start date
Jul 31, 1996
Status verified
Jun 2012
Primary completion
Jun 30, 2001
Completion
Apr 30, 2010

Study Design

Enrollment
9,358 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1
    Arimidex 1mg + Nolvadex placebo
  • Active Comparator: 2
    Arimidex placebo + Nolvadex 20mg
  • Active Comparator: 3
    Arimidex 1mg + Nolvadex 20mg

Primary Outcome Measure

Time to recurrence of breast cancer [ Time Frame: Earliest of local or distant recurrence, new primary breast cancer, or death ]

Related Studies